Sedat Surmeli, MD
Gynecology · Slingerlands, NYNPI 1457306029
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Celularity Inc. at 46.9% of the total. Reporting peaked in 2019 at $1,406 and has fallen 77.0% since, to $324 in 2025.
Across 120 payments — averaging $31.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celularity Inc.$2K
- AbbVie$449
- Sumitomo Pharma America, Inc.$225
- Bayer$206
- Astellas Pharma US Inc$167
- Exeltis, USA Inc.$148
- plus $843 from 21 others
What the payments were for
- Speaking & faculty fees$1,80047%
- Food & beverage$1,98852%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Celularity Inc. | 6 | $1,800 |
| AbbVie(2 entities) | 22 | $449 |
| Sumitomo Pharma America, Inc. | 13 | $225 |
| Bayer | 12 | $206 |
| Astellas Pharma US Inc | 7 | $167 |
| Exeltis, USA Inc. | 8 | $148 |
| Shield Therapeutics Inc | 6 | $105 |
| Coopersurgical, Inc. | 6 | $96 |
| Therapeuticsmd, Inc. | 6 | $93 |
| Myovant Sciences Inc. | 5 | $78 |
| Pfizer | 4 | $71 |
| AMAG Pharmaceuticals, Inc. | 4 | $51 |
| Biogen | 2 | $49 |
| Novo Nordisk | 2 | $44 |
| Mayne Pharma Commercial LLC | 2 | $38 |
| GSK | 2 | $32 |
| Avion Pharmaceuticals | 2 | $29 |
| Dexcom, Inc. | 1 | $24 |
| Lupin Inc. | 2 | $23 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Urovant Sciences Inc | 1 | $17 |
| Meditrina | 1 | $15 |
| Minerva Surgical, Inc | 1 | $14 |
| Duchesnay USA Incorporated | 1 | $13 |
| Aspira Women's Health Inc | 1 | $13 |
| Organon | 1 | $12 |
| Johnson & Johnson | 1 | $9 |
How this compares
$3,839 in reported general payments places this provider in the 85th percentile of 240 gynecology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Raloxifene Hcl | 27 | $1,087 |
| Estradiol | 13 | $762 |
| ValacyclovirValacyclovir Hcl | 11 | $494 |
Paid to pharmacies, not to this prescriber.
Other gynecology in Slingerlands
- Arnold AdvinculaNew York$2.1M
- Stephen CohenSyracuse$204K
- Susan KhalilStaten Island$115K
- Diane SutterKenmore$95K
- Tamara KolevNew York$91K
- Shane SoppSyracuse$84K
- Charles Ascher-WalshNew York$43K
- Paula CastanoNew York$31K
- David KurssWilliamsville$25K
- Navpriya OberoiFayetteville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.